Genentech Reports Strong Phase 3 Enspryng Data in MOGAD
South San Francisco, California, USA – April 21, 2026 In a major breakthrough for rare neurological diseases, Genentech has...
Alzheimer’s Disease Autoimmune Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development EMA FDA fda approval FDA clearance GCP Gene Therapy GMP Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
South San Francisco, California, USA – April 21, 2026 In a major breakthrough for rare neurological diseases, Genentech has...
